DiamiR Biosciences is collaborating with AlzLabs to validate blood-based biomarkers for Alzheimer's disease, measuring phosphorylated tau-217, amyloid ratios, and neurofilament light alongside proprietary microRNA signatures. This work addresses a critical diagnostic gap: replacing expensive, inaccessible PET imaging with accessible blood testing that captures the neurobiological complexity of early-stage disease.
Key Points
- Blood biomarkers correlate with amyloid PET findings in confirmed cases
- MicroRNA signatures provide molecular context beyond protein markers alone
- Integrated multi-marker approach may outperform single-biomarker diagnostics
Longevity Analysis
Early detection of Alzheimer's pathology—before cognitive symptoms emerge—fundamentally shifts intervention timing and accessibility. This research validates whether circulating biomarkers can replace gold-standard imaging, which matters because most populations lack access to specialized neuroimaging. The move toward multi-modal biomarker panels reflects recognition that neurodegeneration involves coordinated changes across multiple biological processes; capturing that complexity through blood testing could democratize screening and enable intervention during the preclinical window when protective strategies are most effective.
Original published by Longevity.Technology, by Kyle Umipig.